All In MedTech

Device Trial Radar · NCT03226626

Tumescent Anesthesia Antibiotic Delivery (TAAD)

Tumescent Anesthesia Antibiotic Delivery (TAAD) and SubQKath for Prevention of Surgical Site Infection, Thrombosis and Sepsis

Last checked: Nov 20, 2026Latest source record: Feb 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

330

Planned (sponsor's estimate)

Start

Dec 1, 2021

Primary completion

Jan 1, 2022

Study completion Jul 31, 2022

Sponsor

Lead sponsor
HK Surgical, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
University of California, Riverside
First posted
Jul 24, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter randomized clinical trial (RCT) comparing two modes of antibiotic delivery: Control: Intravenous Antibiotic Delivery (IVAD) Treatment: IVAD + TAAD The Food \& Drug Administration (FDA) has approved our Investigational New Drug (IND) application to conduct this RCT. An IND application was necessary because subcutaneous injection of antibiotics in general, and cefazolin and metronidazole in particular are considered to be "off-label". In addition, the tumescent formulation of cefazolin (1gm) and metronidazole (500mg/100ml) in a dilute solution of lidocaine (1gm), epinephrine (1mg) in 100ml and sodium bicarbonate (10mEq/10ml) added a 1000ml bag of 0.9% sodium chloride (total volume 1210ml) is also considered "off-label." This trial will also prospectively study the HK Surgical SubQKath, an over-the-needle subcutaneous catheter specifically designed to deliver relatively large volumes of a relatively dilute TAAD solution. The TAAD trial will document the safety and efficacy of the HK SubQKath

Conditions

  • Surgical Site Infection
  • Thrombosis
  • Sepsis

Interventions

  • Tumescent Anesthesia and antibiotic delivery (TAAD) plus IVADDrug

    Concomitant tumescent anesthesia antibiotic delivery (TAAD) \& Intravenous antibiotic delivery (IVAD).

  • SubQKathDevice

    The device intervention consists of using the SubQKath device to provide subcutaneous delivery of antibiotics.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. surgical site infection (SSI)Time frame: within 30 of surgical procedure

3 more outcomes with a free account

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.